Advocacy intelligence hub — real-time data for patient organizations
FINANCIAL LANDSCAPE SUMMARY
Total programs
Everolimus
(EVEROLIMUS)Orphan drugstandardBreckenridge Pharmaceutical, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pat...
Patrick Wen, MD, MD
National Cancer Institute (NCI)
📍 BOSTON, MA
Tobey MacDonald, MD
Pediatric Brain Tumor Consortium
📍 WASHINGTON, DC
Ernest C. Borden, MD
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Stephen Rapp, PhD
Wake Forest University Health Sciences
Elizabeth Fox, MD
National Cancer Institute (NCI)
Timothy F. Cloughesy, MD, MD
Jonsson Comprehensive Cancer Center
📍 LOS ANGELES, CA